Repurposing Immunomodulatory Drugs to Combat Tuberculosis

Fatima, Samreen; Bhaskar, Ashima; Dwivedi, Ved Prakash

doi:10.3389/fimmu.2021.645485

Cited by 33 publications

(26 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A combination of vitD + PBA has been shown to be effective against Mycobacterium tuberculosis through the human antimicrobial peptide (LL-37) pathway [ 56 ]. Repurposing existing drugs that modulates the immune system for anti-tuberculosis therapy is also an interesting approach that is being followed [ 57 ]. Immunomodulatory drugs that have been repurposed include statins, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Linezolid, Metformin, and many others.…”

Section: Non-traditional Approaches To Combat Antibiotic Resistancementioning

confidence: 99%

Emerging Non-Traditional Approaches to Combat Antibiotic Resistance

et al. 2022

View full text Add to dashboard Cite

An increasing number of bacterial pathogens are acquiring resistance to the commonly used antibiotics. This has spurred a global threat leading to a resistance era and has penetrated the consciousness of the common people and the clinicians alike. The delay in discovering new antibiotics has exacerbated the resistance problem, forcing researchers to focus on unconventional antimicrobial therapeutics that differ from conventional antibiotics. Alternative therapies have emerged in recent years, including antimicrobial peptides, phage therapy, efflux pump inhibitors, antibodies, and immunomodulatory agents, which have produced impressive results in both laboratory and in clinical trials. Additionally, ultra-narrow-spectrum therapeutics such as CRISPR-Cas system and peptide nucleic acids aided in the development of sequence-specific antimicrobials. Moreover, combinatorial therapies that combine these new approaches have been efficient enough to get approval for clinical use and have accelerated the discovery of novel combination approaches that enhance the performance of already in-use antibiotics. In this review, we provide an overview of these approaches along with studies that focus on the uncharted microbial territories that have been able to deliver some of the important new antibiotics of recent times. It is hoped that the information gathered in this article will provide an update on the current antibiotic resistance threat and encourage profound research.

show abstract

Section: Non-traditional Approaches To Combat Antibiotic Resistancementioning

confidence: 99%

Emerging Non-Traditional Approaches to Combat Antibiotic Resistance

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Additionally, the repurposing of licensed medications as HDT is considered as a faster approach for market access and lowering industrial development-related costs ( Fatima et al, 2021 ; Oprea et al, 2011 ). In parallel with the interest in drug repurposing and HDT, there has been great interest in new drug delivery approaches to facilitate drug targeting to the site of primary Mtb infection in the lungs and alveolar macrophages ( Batalha et al, 2019 ; Kalombo et al, 2019 ; Dua et al, 2018 ).…”

Section: Host Directed Therapy (Hdt) For Tbmentioning

confidence: 99%

All trans retinoic acid as a host-directed immunotherapy for tuberculosis

Bahlool

Grant

Cryan

et al. 2022

Current Research in Immunology

View full text Add to dashboard Cite

“…Interestingly, as drug repurposing provides a rapid approach to identifying novel therapeutics against Mtb and other intracellular/extracellular bacterial pathogens ( 15 – 18 ), previous screening efforts with different FDA-approved drug libraries have identified several HDTs which could restrict intracellular Mtb growth. All of these drugs induce autophagy of host cells with no significant bactericidal activity against Mtb in axenic culture.…”

Section: Introductionmentioning

confidence: 99%